Furthermore, several studies have demonstrated that PI3Kca mutation resulted in the persistent activation of the PI3K/AKT/mTOR signaling pathway and inhibition of programmed cell death, thereby facilitating the development of resistance to chemotherapy in triple-negative breast cancer (20). This evidence concerns the gene MTOR and triple-negative breast carcinoma.